Docoh
Loading...

GLMD Galmed Pharmaceuticals

News

From Benzinga Pro
Galmed's NASH Candidate Shows Clinically Significant Effect On Fibrosis Improvement
8 Nov 21
Biotech, Earnings, Long Ideas, News, Penny Stocks, Health Care, Movers, Trading Ideas, General
Galmed Pharmaceuticals Q3 EPS $(0.31) Beats $(0.36) Estimate
8 Nov 21
Earnings, News
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.36) by 13.89 percent. This is a 3.13 percent increase over losses of $(0.32) per share
Galmed Announces Data From Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect On Fibrosis Improvement
8 Nov 21
Biotech, News, General
-- Updated liver histology data from first 20 patients show 60% fibrosis improvement by at least 1 stage as early as 24 weeks, data will be presented at AASLD Late Breaker Presentations -- -- Statistically
26 Stocks Moving in Monday's Pre-Market Session
8 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Autolus Therapeutics plc (NASDAQ: AUTL) rose 32.6% to $7.37 in pre-market trading. Syncona said Blackstone Life Science will invest $250 million in Autolus.
Earnings Scheduled For November 8, 2021
8 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
Galmed Reveals Early Aramchol Data From Late-Stage NASH Trial
1 Nov 21
Biotech, Long Ideas, News, Penny Stocks, Health Care, Movers, Trading Ideas, General
Galmed Announces Results From First 16 Patients In Open-Label Part Of ARMOR Study
1 Nov 21
News, FDA
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results from the first
Galmed Pharmaceuticals Announces Results Of Its Phase 2b ARREST Trial Of Aramchol Published In Nature Medicine
11 Oct 21
Biotech, News, General
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the one-year